Floatz logo

CANDESARTAN

Heart Failure

University Hospital, AkershusSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

27 Active assets in the Heart Failure cohort.

Asset / SponsorPhaseRating
Empagliflozin
Jacob Moller
Phase 4BB
Finerenone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
CARVEDILOL
Abramson Cancer Center at Penn Medicine
Phase 3BB
Semaglutide
University Medical Centre Ljubljana
Phase 2/3BB
Rivaroxaban
Janssen Research & Development, LLC
Phase 3B

View all 40 →

Same molecule, other indications

CANDESARTAN is also rated in:

hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
68 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →